Bioequivalence of two oral formulations of clopidogrel tablets in healthy male volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 47, Issue 12, 2009, Pages 780-784

  El Ahmady, O ^a   Ibrahim, M ^a   Hussein, A M ^a   Bustami, R T ^b  

^a Egyptian International Pharmaceutical Industries Company (EIPICO)   (Egypt)

^b Pharmaceutical Research Unit (PRU)   (Jordan)

Author keywords

Bioavailability; Bioequivalence; Clopidogrel; Pharmacokinetics

Indexed keywords

CLOPIDOGREL; THROMBO; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD PRESSURE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG INDUCED HEADACHE; HEART RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 71849117291     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/cpp47780     Document Type: Article

References (13)

1. PDR electronic library.
2. RxList monographs. www.rxlist.com.
3. United States Pharmacopeial Convention, Inc., Drug Information for the Health Care Professional, USPDI, 19th edition. Greenwood Village, CO,USA:Micromedex; 1999.Vol. 1, p. 2508-2512.
4. www.rxmed Pharmaceutical information - PLAVIX®.htm, PLAVIX®™ Oral solution PLAVIX® Tablet.
5. ICH Topic E6, "Guidelines for Good Clinical Practice", Step 5, Consolidated Gideline 1.5.96. Including Step 4 errata, Status: September 1997.
6. Committee for Proprietary Medicinal Products (CPMP), "Note for Guidance on the Investigation of Bioavailability and Bioequivalence". London, 26 July 2001, CPMP/EWP/QWP/1401/98
7. OECD Series on Principles of Good Laboratory Practice and Compliance Monitoring, Number 1. "The OECD Principles of Good Laboratory Practice", Environment Monograph No. 45, Paris 1992.
8. Midha K, Blume H. "Bio-International, Bioavailability, Bioequivalence and Pharmacokinetics", international conference of F.I.P., "Bio-International '92" held in Bad Homburg, Germany, May 20 - 22, 1992, Scientific Publishers Stuttgart.
9. Deng C, Graz J. Generating Randomization Schedules Using SAS® Programming, Statistics and Data Analysis.
10. Code of Federal Regulations, Title 21-Food an Drugs, Volume 5, Revised as of April 1, 2001, From the U.S. Government Printing Office via GPO Access, CITE: 21CFR320.63, Page 200
11. Code of Federal Regulations, Title 21-Food and Drugs, Volume 1, Revised as of April 1, 2001, From the U.S. Government Printing Office via GPOAccess, CITE: 21CFR58.195, Page 313-314
12. Jordanian Law of Pharmaceutical Research, No. 67, 2001.
13. Dilett E, Hausehke D, Steinjans VW. Sample size determination for bioequivelance assessment by means of confidence interval. Int. J Clin Pharmacol. Ther. Toxicol. 1991; 29: 1-8.